Background: The PENPACT-1 trial compared virologic thresholds to determine when to
switch to second-line antiretroviral therapy (ART). Using PENPACT-1 data, we aimed to …

Background The association between baseline drug resistance mutations and subsequent
increase in viral failure has not been established for HIV-infected children. We evaluated …

Objective: To analyze the genotypic resistance profiles of HIV-infected children from rural
China who were experiencing virologic failure to first-line antiretroviral therapy regimens …

Objectives The aim of the study was to assess the prevalence, predictors and patterns of
genotypic resistance mutations in children after failure of World Health Organization …

Objective: To describe the long-term efficacy over 5 years of regimens including
combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in …

Objective To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected
children with virological failure. Methods Children aged 3 months-18 years switching …

BACKGROUND: Children with HIV will be on antiretroviral therapy (ART) longer than adults,
and therefore the durability of first-line ART and timing of switch to second-line are key …

Background: Data on pediatric treatment outcomes and drug resistance while on second-
line antiretroviral therapy (ART) are needed to guide HIV care in resource-limited countries …

China's National Pediatric ART Program began in 2005, in which 32 ART-experienced and
51 antiretroviral therapy (ART)-naïve children received paediatric formulations of …

Abstract Treatment failure and drug resistance create obstacles to long-term management of
HIV-1 infection. Nearly 60% of infected persons fail their first highly active antiretroviral …